T-VEC联合帕博利珠单抗治疗局部晚期或转移性肉瘤的2期临床试验
这项开放标签、单中心2期试验纳入20例至少一线系统治疗失败的局部晚期或转移性肉瘤患者,接受瘤内T-VEC联合静脉帕博利珠单抗治疗。24周最佳客观缓解率(RECIST 1.1)为30%(95%CI 12%-54%,n=6),总体ORR为35%(95%CI 15%-59%,n=7),3级治疗相关不良事件发生率为20%(4例),无4级不良事件或治疗相关死亡。
要点
- T-VEC联合帕博利珠单抗在晚期肉瘤中24周最佳ORR达30%,总体ORR达35%。
- 3级治疗相关不良事件发生率为20%,无4级事件或治疗相关死亡。
- 该联合方案在多种肉瘤组织学亚型中显示抗肿瘤活性,安全性可控。
核心结论
- T-VEC联合帕博利珠单抗在晚期肉瘤中显示抗肿瘤活性,安全性可控,达到预设主要终点。
研究设计与样本
- 开放标签、单中心2期干预性试验,2017年3月16日至12月4日入组20例至少一线系统治疗失败的局部晚期或转移性肉瘤患者,中位治疗时长16周(范围7-67周),分析数据截至2018年12月14日。
主要发现
- 24周最佳ORR(RECIST 1.1)为30%(95%CI 12%-54%,n=6),总体ORR为35%(95%CI 15%-59%,n=7)。
- 3级治疗相关不良事件发生率为20%(4例),无4级治疗相关不良事件或治疗相关死亡。
临床怎么用
- 对于至少一线系统治疗失败的局部晚期或转移性肉瘤患者,可考虑T-VEC联合帕博利珠单抗作为可选方案,尤其适用于多种组织学亚型。
局限性
- 单中心、开放标签、样本量小(20例),缺乏随机对照,结论需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with advanced sarcoma have limited treatment options. Talimogene laherparepvec (T-VEC) has been shown to increase tumor-specific immune activation via augmenting antigen presentation and T-cell priming. OBJECTIVE: To examine whether T-VEC in combination with pembrolizumab is associated with increased tumor-infiltrating lymphocyte infiltration and programmed death-ligand 1 expression and thus with increased antitumor activity in patients with locally advanced or metastatic sarcoma. DESIGN, SETTING, AND PARTICIPANTS: This open-label, single-institution phase 2 interventional trial of T-VEC plus pembrolizumab enrolled 20 patients with locally advanced or metastatic sarcoma between March 16 and December 4, 2017, for whom at least 1 standard systemic therapy had failed. The median duration of therapy was 16 weeks (range, 7-67 weeks). Reported analyses include data through December 14, 2018. INTERVENTION: Patients received pembrolizumab (200-mg flat dose) intravenously and T-VEC (first dose, ≤4 mL × 106 plaque-forming units [PFU]/mL; second and subsequent doses, ≤4 mL × 108 PFU/mL) injected into palpable tumor site(s) on day 1 of each 21-day cycle. MAIN OUTCOMES AND MEASURES: The primary end point was objective response rate (ORR; complete response and partial response) at 24 weeks determined by Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1, criteria. Secondary end points included best ORR by immune-related RECIST criteria, progression-free survival rate at 24 weeks, overall survival, and safety. RESULTS: All 20 patients (12 women [60%]; median age, 63.5 years [range, 24-90 years]) were evaluable for response. The study met its primary end point of evaluating the best ORR at 24 weeks determined by RECIST, version 1.1, criteria; the best ORR was 30% (95% CI, 12%-54%; n = 6). The ORR overall was 35% (95% CI, 15%-59%; n = 7). The incidence of grade 3 treatment-related adverse events was low (4 patients [20%]). There were no grade 4 treatment-related adverse events or treatment-related deaths. CONCLUSIONS AND RELEVANCE: In this phase 2 clinical trial, treatment with T-VEC plus pembrolizumab was associated with antitumor activity in advanced sarcoma across a range of sarcoma histologic subtypes, with a manageable safety profile. This combination therapy met its predefined primary study end point; further evaluation of T-VEC in combination with pembrolizumab for patients with select sarcoma subtypes is planned. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT03069378.
引用
- Kelly CM, Antonescu CR, Bowler T, et al. Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial. JAMA Oncol. 2020. PMID: 31971541. doi:10.1001/jamaoncol.2019.6152
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。